MedTrace Logo

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

NCT02453711 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 957

Last updated 2020-04-17

Study results available
· View outcomes & findings →

Summary

This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.

Conditions

  • Metabolism and Nutrition Disorder
  • Obesity

Interventions

DRUG

semaglutide

Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

DRUG

liraglutide

Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

DRUG

placebo

Once-daily subcutaneous (s.c., under the skin) administration.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2017-03-30
Completion
2017-04-12

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Germany
  • Israel
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02453711 on ClinicalTrials.gov